Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 16;18(1):101.
doi: 10.1186/s12955-020-01354-8.

Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review

Gian Loreto D'Alò  1   2 , Franco De Crescenzo  3   4   5 , Silvia Minozzi  1 , Gian Paolo Morgano  6 , Zuzana Mitrova  1 , Maria Luisa Scattoni  7 , Laura Amato  1 , Marina Davoli  1 , Holger J Schünemann  6   8 ; ISACA guideline working group
Collaborators, Affiliations

Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review

Gian Loreto D'Alò et al. Health Qual Life Outcomes. .

Abstract

Introduction: Some recent randomized controlled trials (RCTs) assessed the efficacy and safety of polyunsaturated fatty acids (PUFAs) for the treatment of autism spectrum disorder (ASD). To optimally inform the Italian guideline for the management of ASD in children and adolescents, we reviewed the impact on equity, acceptability and feasibility for developing a pilot recommendation for PUFAs.

Methods: We performed a rapid systematic review of observational and experimental studies on PUFAs for children and adolescents with ASD, extracting data on resources required, equity, acceptability, and feasibility of PUFAs. We followed the framework provided by the grading of recommendations assessment, development and evaluation (GRADE) methodology, and we assessed risk of bias and methodological quality of included studies. Results were synthesized both narratively and quantitatively to address clinically relevant questions on equity, acceptability, and feasibility.

Results: We found 14 papers related to equity. PUFAs did not seem to impact equity importantly. We did not find variation in effectiveness across subgroups and in a base case scenario, the cost of a 12 weeks cycle of therapy with 1.155 g/day of PUFAs was €65.51 euro. The acceptability of PUFAs was evaluated in 17 studies, 9 of which were RCTs. PUFAs were widely used among children and adolescents with ASD (18 to 51%), and 50% of parents considered nutritional supplementation as useful. Difficulty in swallowing capsules and bad taste were identified as possible causes of poor compliance, but treatment adherence, when measured in included RCTs, was judged to be good to excellent. Discontinuation due to any cause for PUFAs could not differ from placebo (low certainty of evidence). The feasibility of using PUFAs was assessed in 12 studies. PUFAs were probably sustainable, and no particular critical issue emerged from the feasibility assessment. However, the evidence appeared scarce and indirect.

Conclusions: We found the administration of PUFAs in children and adolescents with ASD to be potentially equitable, acceptable and feasible. These results are limited by the limited number and quality of retrieved documents, and need to be viewed in light of efficacy and safety data to formulate clinical recommendations.

Keywords: Autism spectrum disorder; Clinical practice guidelines; Cost-analysis; Polyunsaturated fatty acids; Treatment adherence and compliance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram
See this image and copyright information in PMC

References

    1. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018;392(10146):508–520. doi: 10.1016/S0140-6736(18)31129-2. - DOI - PMC - PubMed
    1. Istituto Superiore di Sanità . Giornata mondiale della Consapevolezza dell’Autismo: in Italia un bimbo ogni 77. 2019.
    1. CDC. Summary of Autism Spectrum Disorder (ASD) Prevalence Studies. Available at: www.cdc.gov/ncbddd/autism/documents/ASDPrevalenceDataTable2016.pdf. Last access: 12/31/2018.
    1. Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–728. doi: 10.1001/jamapediatrics.2014.210. - DOI - PubMed
    1. Operto FF, Martino F, Rinaldi A, et al. Long-term outcome of autistic spectrum disorder: a retrospective case study in a southern italian region. Ital J Pediatr. 2017;43(1):83. doi: 10.1186/s13052-017-0399-z. - DOI - PMC - PubMed

Publication types

Substances